Leonor et al found that time under AIs is an independent risk factor for joint pain and bone loss, with reduced disease-free survivalin patients.[4] In the IBIS-II prevention trial, patients who took anastrozole for 5 years had a significant decrease in bone mineral density.[5] Nearly 10% of breast cancer patients discontinued AIs due to aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).[6]. Here, CYP19A1 is linked to breast carcinoma.